BREAKING
Nexxen Q4 FY26 Earnings Results 17 hours ago Daktronics Q3 FY26 Earnings Results 17 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 20 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 21 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 2 days ago Best Buy 4Q 2026: Earnings Analysis 2 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 3 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 3 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 3 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 6 days ago Nexxen Q4 FY26 Earnings Results 17 hours ago Daktronics Q3 FY26 Earnings Results 17 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 20 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 21 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 2 days ago Best Buy 4Q 2026: Earnings Analysis 2 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 3 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 3 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 3 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 6 days ago
ADVERTISEMENT
AlphaGraphs

YY’s revenue surges 67% in Q2

Chinese social media company YY Inc (NASDAQ: YY) reported a revenue increase of 67% to RMB6.295 billion (US$917.0 million) from RMB3,773.2 million in the corresponding…

Market News

Bio-Path likely to report wider Q2 loss on Aug. 15

Bio-Path Holdings (NASDAQ: BPTH) is expected to continue incurring significant operating losses in the second quarter. Also, the losses are likely to increase substantially as…

Market News

CorMedix narrows loss in Q2, revenue miss estimates

CorMedix (NYSE: CRMD) reported mixed second quarter results after the bell. Revenue failed to beat estimates, while earnings came in better-than-expected. Last month, the biopharma…